OVERALL SURVIVAL WITH DARATUMUMAB, BORTEZOMIB, MELPHALAN, AND PREDNISONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (ALCYONE): A RANDOMISED, OPEN-LABEL, PHASE 3 TRIAL

Share

Share on facebook
Share on linkedin
Share on twitter
Share on email

A clinical trial published in The Lancet demonstrates the benefits of a new combination of drugs for the treatment of multiple myeloma. This new treatment “significantly improves the survival of newly diagnosed patients of this disease without the option of bone marrow transplantation.”

The Alcyone study is a phase III clinical trial, conducted on 706 patients for more than three years, which shows that adding the Daratumumab to the traditional treatment formed by the combination of Bortezomib, Melphalan and Prednisone improves overall survival in patients with multiple myeloma.